Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | VEGFA | P15692 | 4/20 | 0.31 |
| ▸ | BMP2 | P12643 | 1/20 | 0.31 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.31 |
| ▸ | SHH | Q15465 | 1/20 | 0.31 |
| ▸ | FGF1 | P05230 | 3/20 | 0.31 |
| ▸ | FGF2 | P09038 | 3/20 | 0.31 |
| ▸ | HPSE | Q9Y251 | 3/20 | 0.31 |
| ▸ | SELL | P14151 | 8/20 | 0.31 |
| ▸ | SELP | P16109 | 8/20 | 0.31 |
| ▸ | BCHE | P06276 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15975977 | 0.91 | GBA1 (0.36) | GBA1CYP3A4MAPK1SELLSELP | |
| SCHEMBL15975985 | 0.85 | ALDH1A1 (0.37) | GBA1CYP3A4MAPK1BCHE | |
| SCHEMBL16770477 | 0.85 | ALDH1A1 (0.37) | GBA1CYP3A4MAPK1BCHE | |
| SCHEMBL15975868 | 0.85 | ALDH1A1 (0.37) | GBA1CYP3A4MAPK1BCHE | |
| SCHEMBL13699176 | 0.82 | GJB2 (0.41) | VEGFABMP2CXCL12SHHFGF1 | |
| SCHEMBL16492113 | 0.81 | GBA1 (0.39) | GBA1CYP3A4MAPK1BCHE | |
| SCHEMBL15975866 | 0.79 | GBA1 (0.42) | GBA1CYP3A4MAPK1BCHE | |
| SCHEMBL15976022 | 0.78 | TNF (0.38) | GBA1CYP3A4MAPK1BCHE | |
| SCHEMBL13166717 | 0.78 | BCHE (0.43) | GBA1CYP3A4MAPK1BCHE | |
| SCHEMBL15975989 | 0.78 | BCHE (0.43) | GBA1CYP3A4MAPK1BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150050282-A1 | GLYCOCONJUGATES AND USE THEREOF AS VACCINE AGAINST SHIGELLA FLEXNERI SEROTYPE 3a AND X | INSTITUT PASTEUR (FR) | 2015-02-19 | — | — | US | disclosed |
| US-8815239-B2 | Glycoconjugates and use thereof as vaccine against Shigella flexneri serotype 3a and X | INSTITUT PASTEUR (FR) | 2014-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150050282-A1 | GLYCOCONJUGATES AND USE THEREOF AS VACCINE AGAINST SHIGELLA FLEXNERI SEROTYPE 3a AND X | ST3GAL3, SI, STT3A | GBA1 296/4885CYP3A4 4622/4885MAPK1 1863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.